For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The Canadian Cancer Trials Group (CCTG), the European Organisation for Research and Treatment of Cancer (EORTC), and the UK Collaborative for Cancer Clinical Research (UK3CR) welcome the G7 Leaders’ announcement recognizing cancer as a global priority and calling for stronger international cooperation to improve outcomes for patients[i].
Canada, Europe, UK and G7 partners have a longstanding history of collaboration in cancer research and clinical trials. Through international academic trial networks and the broader oncology community, researchers and clinicians have worked across borders for decades to test new treatments, improve standards of care, reduce side effects and enhance quality of life for people affected by cancer.
Academic cancer clinical trials are among the fastest, most independent and most patient-centred ways to translate innovation into routine care. By rigorously evaluating new treatments, technologies and care strategies in real-world health systems, they generate trusted, unbiased evidence that helps clinicians, patients and policymakers understand what works, for whom, and at what cost.
The G7 commitment comes at a critical time. Cancer trials are increasingly complex, costly and administratively burdensome, while many patients still face barriers to participation based on geography, resources and access to specialized testing. Greater cooperation among Canada, the European Union, UK and G7 partners can help reduce duplication, streamline regulatory and ethics processes, improve data sharing, and expand access to trials for more patients.
CCTG, EORTC and UK3CR call on governments and research funders to provide sustained funding for academic cancer clinical-trial infrastructure. Public investment is essential to answer questions that matter most to patients and health systems, including how to improve survival, reduce treatment burden, support rare and hard-to-treat cancers, and ensure that advances reach patients faster and more equitably.
“Academic clinical trials are the engine that turns discovery into better cancer care,” said Dr. Janet Dancey, CCTG Chair. “By strengthening Canadian, European and G7 collaboration, we can accelerate innovation, reduce unnecessary burden, generate trusted evidence, and deliver better outcomes for patients.”
CCTG, EORTC and UK3CR cancer clinical trial organizations stand ready to work with governments, funders, regulators, health systems, patient partners, clinicians, scientists and industry to build on decades of collaboration and advance the next generation of cancer clinical trials.
A new clinical trial has opened in Canada for patients with peripheral T-cell lymphoma (PTCL), investigating whether an intensive treatment approach can reduce the risk of the disease returning after initial chemotherapy.
ALC.10 (MM1OA-EA02), another myeloMATCH study, has opened in Canada comparing the usual treatment for FLT3 mutated acute myeloid leukemia (AML) with a new drug using two different treatment schedules to see if it improves outcomes for older patients. In this study the drug gilteritinib, a class of medications called kinase inhibitors, will be added to the current two drug treatment.
The results of the BR.31 global Phase III study, testing adjuvant durvalumab in patients with completely resected non–small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology.
Pausing endocrine treatment to attempt pregnancy can be considered - no additional risk of recurrences after 5 years. The MAC18 (POSITIVE) study, evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women
The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) announced the enrollment of the first patient in the third sub study IND240C of their ongoing Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC).
Results from the primary analysis of the ctDNA-negative cohort from the international DYNAMIC-III (CO.29) clinical trial were presented during the Presidential Symposium of the European Society for Medical Oncology Congress in Berlin
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
Combination Therapy with Luspatercept in Lower Risk Myelodysplasia: A Tier 1 myeloMATCH Substudy
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
One of the world’s largest randomized clinical trials, investigating the use of fecal microbiota transplantation (FMT) has opened in Canada.
MAC30 has recently opened in Canada and will compare two commonly used treatment choices for premenopausal women with ER-positive/HER2-negative breast cancer and a low to intermediate risk of recurrence.
A new CCTG national study has received funding from the Social Sciences and Humanities Research Council and Genome Canada to explore the ethical questions raised with emerging cancer technologies like CAR-T cell therapy.
